Stock Financial Ratios

FENCF / Fennec Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)67.68
Enterprise Value ($M)44.66
Book Value ($M)3.57
Book Value / Share0.28
Price / Book7.64
NCAV ($M)3.57
NCAV / Share0.28
Price / NCAV-65.71
Income Statement (mra) ($M)
Net Income-2.79
Balance Sheet (mrq) ($M)
Cash & Equivalents9.69
Cash / Share0.76
Quick Ratio0.00
Current Ratio0.00
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.78
Return on Assets (ROA)-0.70
Return on Equity (ROE)-0.78
Identifiers and Descriptors
Central Index Key (CIK)1211583
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Share Statistics
Common Shares Outstanding (M)15.87
Scoring Models
Piotroski F Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Additional Paid In Capital Per Share3.42
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Liabilities And Stock Equity Per Share0.77
Liabilities Current Per Share0.08
Inventory Per Share0.00
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Retained Earnings Per Share-9.33
Assets Per Share0.77
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Equity Per Share0.69
Property Plant And Equipment Net Per Share0.00
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Liabilities Per Share0.08
Assets Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Cash And Equivalents Per Share0.76
Assets Current Per Share0.00
Cash Per Share0.76
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00

Related News Stories

Otonomy's $525 Million Dive Is Fennec's Good Fortune

2017-11-02 seekingalpha
Over the last six months, Fennec has uplisted, raised $7.6M above market, and released positive Phase 3 data. (102-5)

BRIEF-Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark

2017-10-16 reuters
* Fennec announces positive results from phase 3 SIOPEL 6 study on Pedmark (sodium thiosulfate) presented at the 49th Congress of the international Society of Pediatric Oncology (SIOP) 2017 meeting (2-0)

Even More Biopharma and FDA Catalysts Coming in October

2017-10-07 247wallst
As the markets continue to hit all-time highs, biotech and pharmaceutical companies have been part of these massive gains. There is a very positive sentiment in the health care sector as it’s been one of the best performing this year, second to technology in the S&P 500. (61-3)

CUSIP: 31447P100